



S/N 10/601,059

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Shu-Ping Yang et al.	Examiner:	Unknown
Serial No.:	10/601,059	Group Art Unit:	1646
Filed:	June 20, 2003	Docket:	1443.064US1
Title:	ANTI-CHRONDROSARCOMA COMPOUNDS		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :10/601,059

Filing Date: June 20, 2003

Title: ANTI-CHONDROSARCOMA COMPOUNDS

Page 2

Dkt: 1443.064US1


The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

SHU-PING YANG ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(516) 795-6820




Date September 23, 2005

By _____
Robin A. Chadwick
Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 23rd day of September, 2005.

JAMES KAUSIK
Name

[Signature]
Signature



Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)

Complete if Known	
Application Number	10/601,059
Filing Date	June 20, 2003
First Named Inventor	Yang, Shu-Ping
Group Art Unit	1646
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 1443.064US1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	WO-03/018748A2	03/06/2003	Quirk, S., et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		COPPOLA, G., et al., "Effect of Intraperitoneally, Intravenously and Intralesionally Administered Monoclonal Anti- β -FGF Antibodies on Rat Chondrosarcoma Tumour Vascularization and Growth", <u>Anticancer Research</u> , 17(3C), (1997),2033-2040	
		DAILEY, L., et al., "A Network of Transcriptional and Signaling Events is Activated by FGF to Induce Chondrocyte Growth Arrest and Differentiation", <u>The Journal of Cell Biology</u> , 161(6), (2003),1053-1066	
		FUJISAWA, N., et al., "Inhibitory Effects of Transforming Growth Factor - β 1 Pretreatment on Experimental Pulmonary Metastasis of MCS-1 Chinese Hamster Mesenchymal Chondrosarcoma Cells", <u>Tohoku J. Exp. Med.</u> , 187, (1999),203-213	
		GIGANT-HUSELSTEIN, C., et al., " <i>In vitro</i> Study of Intracellular IL-1 β Production and β 1 Integrins Expression in Stimulated Chondrocytes - Effect of Rhein", <u>Biorheology</u> , 39(1, 2), (2002),277-285	
		KEARNS, A. E., "Initiation of Chondroitin Sulfate Biosynthesis: A Kinetic Analysis of UDP-D-Xylose: Core Protein β -D-Xylosyltransferase", <u>Biochemistry</u> , 30(30), (1991),7477-7483	
		LIACINI, A., et al., "Induction of Matrix Metalloproteinase-13 Gene Expression by TNF- α is Mediated by MAP Kinases, AP-1, and NF- κ B Transcription Factors in Articular Chondrocytes", <u>Experimental Cell Research</u> , 288(1), (2003),208-217	
		RAUCCI, A., et al., "Activation of the ERK1/2 and p38 Mitogen-Activated Protein Kinase Pathways Mediates Fibroblast Growth Factor-Induced Growth Arrest of Chondrocytes", <u>The Journal of Biological Chemistry</u> , 279(3), (2004),1747-1756	
		RODRIGUEZ-MANZANEQUE, J. C., et al., "ADAMTS1 Cleaves Aggrecan at Multiple Sites and is Differentially Inhibited by Metalloproteinase Inhibitors", <u>Biochemical and Biophysical Research Communications</u> , 293(1), (2002),501-508	
		SAHNI, M., et al., "FGF Signaling Inhibits Chondrocyte Proliferation and Regulates Bone Development Through the STAT-1 Pathway", <u>Genes & Development</u> , 13(11), (1999),1361-1366	
		SEONG, S.-C., et al., "Insulin-Like Growth Factor I Regulation of Swarm Rat Chondrosarcoma Chondrocytes in Culture", <u>Experimental Cell Research</u> , 211, (1994),238-244	
		WU, C., et al., "Furin-Mediated Processing of Pro-C-Type Natriuretic Peptide", <u>The Journal of Biological Chemistry</u> , 278(28), (2003),25847-25852	

EXAMINER

DATE CONSIDERED